Metal‐Free Hydrosilylation of Ketenes with Silicon Electrophiles: Access to Fully Substituted Aldehyde‐Derived Silyl Enol Ethers
作者:Avijit Roy、Martin Oestreich
DOI:10.1002/chem.202100877
日期:2021.6.4
catalysts is reported. The boron Lewis acid tris(pentafluorophenyl)borane accelerates the slow uncatalyzed reaction of ketenes and hydrosilanes, thereby providing a convenient access to the new class of β,β-di- and β-monoaryl-substituted aldehyde-derived silyl enolethers. Yields are moderate to high, and Z configuration is preferred. The corresponding silyl bis-enol ethers are also available when using
Origins of Diastereoselectivity in Lewis Acid Promoted Ketene–Alkene [2 + 2] Cycloadditions
作者:Christopher M. Rasik、Young J. Hong、Dean J. Tantillo、M. Kevin Brown
DOI:10.1021/ol5025184
日期:2014.10.3
A detailed analysis of a Lewis acid promoted ketene–alkene [2 + 2] cycloaddition is reported. The studies have led to a rationalization for an observed inversion of diastereoselectivity between thermally induced and Lewis acid promoted ketene–alkene [2 + 2] cycloadditions. The model is supported with both experimental and computational results.
1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF
申请人:GENFIT
公开号:US20140350112A1
公开(公告)日:2014-11-27
The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
[EN] 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE 1,3-DIPHÉNYLPROPANE, PRÉPARATIONS ET UTILISATIONS ASSOCIÉES
申请人:GENFIT
公开号:WO2013098374A1
公开(公告)日:2013-07-04
The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders,such as Alzheimer'sdisease, Parkinson's disease and multiple sclerosis.
A novel sequential reaction that combines a visible light-induced Wolffrearrangement of α-diazoketones and a Pd-catalyzed [3+2] cycloaddition of vinyl cyclopropanes with the resulting ketenes is described in this work. Selective O-allylic alkylation was observed over C-allylic alkylation, which unexpectedly led to a series of highly functionalized tetrahydrofurans with high efficiency (20 examples